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doi:10.1Objective:Microvascular malperfusion after myocardial infarction leads to infarct expansion, adverse remodel-
ing, and functional impairment. Native reparative mechanisms exist but are inadequate to vascularize ischemic
myocardium. We hypothesized that a 3-dimensional human fibroblast culture (3DFC) functions as a sustained
source of angiogenic cytokines, thereby augmenting native angiogenesis and limiting adverse effects of myocar-
dial ischemia.
Methods: Lewis rats underwent ligation of the left anterior descending coronary artery to induce heart failure;
experimental animals received a 3DFC scaffold to the ischemic region. Border-zone tissue was analyzed for
the presence of human fibroblast surface protein, vascular endothelial growth factor, and hepatocyte growth fac-
tor. Cardiac function was assessed with echocardiography and pressure–volume conductance. Hearts underwent
immunohistochemical analysis of angiogenesis by co-localization of platelet endothelial cell adhesion molecule
and alpha smooth muscle actin and by digital analysis of ventricular geometry. Microvascular angiography was
performed with fluorescein-labeled lectin to assess perfusion.
Results: Immunoblotting confirmed the presence of human fibroblast surface protein in rats receiving 3DFC,
indicating survival of transplanted cells. Increased expression of vascular endothelial growth factor and hepa-
tocyte growth factor in experimental rats confirmed elution by the 3DFC. Microvasculature expressing platelet
endothelial cell adhesion molecule/alpha smooth muscle actin was increased in infarct and border-zone regions
of rats receiving 3DFC. Microvascular perfusion was also improved in infarct and border-zone regions in these
rats. Rats receiving 3DFC had increased wall thickness, smaller infarct area, and smaller infarct fraction.
Echocardiography and pressure–volume measurements showed that cardiac function was preserved in these
rats.
Conclusions:Application of a bioengineered 3DFC augments native angiogenesis through delivery of angiogenic
cytokines to ischemic myocardium. This yields improved microvascular perfusion, limits infarct progression and
adverse remodeling, and improves ventricular function. (J Thorac Cardiovasc Surg 2010;140:667-76)SIschemic cardiovascular disease is an increasingly prevalent
global health concern. Traditionally, patients with ischemic
cardiomyopathy are treated with either percutaneous coro-
nary intervention or bypass surgery. However, a significant
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/Bcoronary disease. Additionally, conventional revasculariza-
tion methods do not adequately address the microvascular
destruction that accompanies a significant ischemic myocar-
dial injury.1-4 These factors have driven investigators to
develop novel revascularization techniques that specifically
target the microvasculature in ischemic myocardium.5-7
Induction of microvascular angiogenesis by angiogenic
growth factors has been studied as one such approach. Vas-
cular endothelial growth factors (VEGFs) are potent in-
ducers of vascular growth and have been shown to
produce transmural angiogenesis and improve myocardial
perfusion.8-10 Hepatocyte growth factor (HGF) likewise
enhances myocardial angiogenesis, limits apoptosis, and
improves postinfarct cardiac function.11-13
Despite these promising results, optimal delivery of
angiogenic growth factors remains problematic. Systemic
or intracoronary delivery, while preferable owing to ease
of use and clinical applicability, does not achieve adequate
concentrations in the myocardium to maximize efficacy.rdiovascular Surgery c Volume 140, Number 3 667
Abbreviations and Acronyms
a-SMA ¼ alpha smooth muscle actin
3DFC ¼ 3-dimensional human dermal
fibroblast culture
dP/dt max ¼ maximum rate of pressure rise
EDV ¼ end-diastolic volume
ESV ¼ end-systolic volume
HFSP ¼ human fibroblast surface protein
HGF ¼ hepatocyte growth factor
IU ¼ intensity units
LAD ¼ left anterior descending coronary
artery
LV ¼ left ventricular
LVID ¼ left ventricular internal diameter
LVIDd ¼ left ventricular end-diastolic diameter
LVIDs ¼ left ventricular end-systolic diameter
PECAM ¼ platelet endothelial cell adhesion
molecule
SCID ¼ severe combined immunodeficient
VEGF ¼ vascular endothelial growth factor




STherefore, local delivery is desired to maximize effect.14
Although recombinant proteins have a good safety profile,
delivery via either direct myocardial injection or percutane-
ous catheter-based injection is confined to a single adminis-
tration, temporally limiting the effects. Alternatively, viral
gene transfer may achieve greater efficacy but is hampered
by immune factors that may cause toxicity and diminished
transgene expression.15 The ideal delivery vehicle would
achieve sustained growth factor expression in the zone of
interest with limited toxicity.
Although a bioengineered sustained delivery mechanism
is appealing, perhaps the ideal method of achieving pro-
longed local expression of angiogenic growth factors is
recruitment or transplantation of fibroblasts. As a key medi-
ator of wound healing and angiogenesis, fibroblasts are
a robust source of VEGF and HGF, as well as other known
and unknown factors. Additionally, a cellular source is more
likely than a bioengineered delivery system to secrete the
precise concentrations of growth factors required for an op-
timal angiogenic response. Because multiple investigators
have shown that direct myocardial injection of cells results
in poor cell survival,16-19 and studies show that cell-seeded
biocompatible sheets result in improved cell engraft-
ment,20,21 the current study uses a tissue-engineered,
3-dimensional human dermal fibroblast culture (3DFC)
scaffold as a sustained local source of angiogenic growth
factors. A similar 3DFC (Dermagraft; Advanced BioHeal-
ing, Inc, La Jolla, Calif) is approved by the Food and Drug
Administration in the treatment of diabetic foot ulcers and
is a safe, effective method of improving ulcer closure.22668 The Journal of Thoracic and Cardiovascular SurgOur 3DFC, composed of structural extracellular matrix pro-
teins and human dermal fibroblasts, currently marketed as
Anginera (Theregen, Inc, San Francisco, Calif), is being
studied as an angiogenic therapy for myocardial ischemia.
Two previous studies have shown that the 3DFC supports
myocardial angiogenesis and attenuates reduction in cardiac
function in a severe combined immunodeficient (SCID)
mouse model of ischemic cardiomyopathy.23,24
The purpose of this study is to examine in depth the angio-
genic mechanisms of the 3DFC. It is hypothesized that the
3DFC serves as a sustained local source of VEGF and
HGF to support angiogenesis after ischemic myocardial
injury. It is further hypothesized that enhanced microvascu-
lar perfusion results in diminished adverse ventricular
remodeling and cardiac functional loss in a rat model of
ischemic cardiomyopathy.METHODS
The 3DFC (Figure 1), composed of fibroblasts cultured on pieces of pol-
yglycolic acid mesh, was stored at80C and then rapidly thawed, rinsed,
and used immediately according to the previously published protocol.25
In Vitro Growth Factor Expression
A portion of 3DFC was cultured in endothelial basal medium-2 (Lonza
Walkersville, Inc, Walkersville, Md), free of growth factors and supple-
ments. A time course of growth factor expression by the 3DFC was gener-
ated. Media samples were collected at 0.5, 1, 1.5, 2, 3, 4, 10, and 24 hours
after culture and analyzed via enzyme-linked immunosorbent assay for
human VEGF-A (R&D Systems, Minneapolis, Minn) and human HGF
(R&D Systems). Media-only samples served as a control.
Animal Care and Biosafety
Male Lewis rats weighing 250 to 300 g were obtained from Charles
River (Boston, Mass). Food and water were provided ad libitum. This study
was performed in accordance with the standard humane care guidelines
of the ‘‘Guide for the Care and Use of Laboratory Animals’’ and the
Institutional Animal Use and Care Committee of the University of Pennsyl-
vania.
Ischemic Cardiomyopathy Model
Per a previously published protocol,26 rats were anesthetized with ket-
amine (75mg/kg) and xylazine (7.5 mg/kg), intubated with a 16-gauge cath-
eter, and mechanically ventilated (Hallowell EMC, Pittsfield, Mass) with
a tidal volume (mL) ¼ 6.2 3M1.01 (M ¼ animal mass, kg) and respiratory
rate (min1) ¼ 53.5 3 M0.26. A thoracotomy was performed in the left
fourth intercostal space. A 7-0 polypropylene suture was placed around
the mid–left anterior descending coronary artery (LAD) and ligated to pro-
duce a large anterolateral myocardial infarction of 30% of the left ventricle.
The extent of infarction is highly reproducible in our hands and cardiomy-
opathy has been well documented.11,27-29 In experimental animals, a 3DFC
scaffold (0.75 3 0.75 cm2) was sutured to the ischemic area. Control ani-
mals received a similar array of sutures with no scaffold. Notably, the
two previous SCID mouse 3DFC studies showed no significant angiogenic
response in animals treated with an acellular scaffold, suggesting that the an-
giogenic response results entirely from the cellular component of the
3DFC.23,24 A fibroblast implantation control group was not used because
the poor survivability of therapeutic cells when directly injected into ische-
mic myocardium would render this an inadequate control population.16-19
The thoracotomywas closed and animals were implanted with identificationery c September 2010
FIGURE 1. Scanning electron microscopy images of the 3-dimensional fi-
broblast culture (3DFC). The 3DFC consists of a bioabsorbable scaffold, ex-
tracellular matrix proteins, and viable human dermal fibroblasts. A, 993; B,
2003; C, 10003.




Smicrochips (BioMedic Data Systems Inc, Seaford, Del) and allowed to re-
cover. Identification data were maintained by an investigator who did not
participate in subsequent data collection or analysis. Four weeks following
LAD ligation, animals underwent the following experiments.The Journal of Thoracic and CaDetermination of Human Fibroblast Cell Fate
To determine the presence of transplanted fibroblast components, we ex-
planted hearts from a subset of animals (control, n¼ 4; experimental, n¼ 4)
4 weeks after LAD ligation. Myocardial tissue biopsy specimens were taken
from the ischemic zone, including the scaffold in 3DFC animals. Samples
were homogenized in T-Per Tissue Extraction Reagent (Thermo-Fischer,
Rockford, Ill), normalized for total protein content via Quick Start Bradford
Protein Assay (Bio-Rad Laboratories, Hercules, Calif), and tested for the
presence of human fibroblast surface protein (HFSP). Immunoblotting
was performed with a mouse antibody directed against HFSP (1:300; Ab-
cam, Cambridge, Mass), and sheep anti-mouse secondary antibodies
(1:100,000; GE Healthcare, Piscataway, NJ). Detection was performed
with SuperSignal West Dura Extended Duration Substrate (Thermo Scien-
tific, Rockford, Ill).
In Vivo Growth Factor Expression/Mechanism of
Action
We assayed for the presence of human VEGF-A and human HGF by im-
munoblotting to determine in vivo expression of angiogenic growth factors
after 3DFC implantation (control, n ¼ 4; experimental, n ¼ 4). Myocardial
tissue biopsy specimens were processed as described earlier, and immuno-
blotting was performed with a mouse antibody directed against human
VEGF-A (1:750, Abcam) and a rabbit antibody directed against human
HGF (1:1000, Santa Cruz Biotechnology, Santa Cruz, Calif). Secondary an-
tibodies were sheep anti-mouse (1:40,000, GE Healthcare) and donkey anti-
rabbit (1:30,000, GE Healthcare). Detection was performed as described
earlier.
Assessment of Microvascular Density
Microvascular angiogenesis was assessed in the ischemic zone (control,
n ¼ 10; experimental, n ¼ 9). Explanted hearts were distended with OCT
compound (Sakura Finetek, Torrance, Calif), submerged in an OCT-filled
reservoir, frozen, and stored at80C. Transverse 10-mm sections were pre-
pared through the infarct level and co-stained with antibodies directed
against platelet endothelial cell adhesion molecule (PECAM) and alpha
smooth muscle actin (a-SMA). Sections were incubated with mouse anti-
PECAM (1:500; BD Biosciences, San Jose, Calif) and rabbit anti-a-SMA
(1:500, Abcam) for 1 hour. Sections were then washed and incubated
with Alexa Fluor 555 donkey anti-mouse immunoglobulin G (1:500, Invi-
trogen Corporation, Carlsbad, Calif) and Alexa Fluor 488 donkey anti-rab-
bit immunoglobulin G (1:500, Invitrogen) for 1 hour. Slides were washed
and mounted with Vectashield (Vector Laboratories, Inc, Burlingame,
Calif). Quantitative analysis of vessels co-staining for PECAM and
a-SMA was conducted with 403 fluorescent microscopy in the infarct
zone, peri-infarct border zone, and remote myocardium. Counts were con-
ducted in a group-blinded fashion in 4 fields per specimen for each of the
three zones and averaged.
Assessment of Microvascular Perfusion With Lectin
Angiography
To ensure that newly formed microvessels were functionally per-
fused, we subjected a subset of animals (control, n ¼ 3; experimental,
n ¼ 3) to lectin microvascular angiography. We injected 500 mg/kg of
fluorescein-labeled Lycopersicon esculentum (tomato) lectin (Vector
Laboratories) into the inferior vena cava and allowed it to circulate
with a beating heart for 5 minutes. Direct contact of lectin with endothe-
lial cells is required for binding to the surface N-acetylglucosamine olig-
omers of endothelial cells, so only perfused vessels are labeled.30 After
lectin perfusion, hearts were explanted. Image stacks were obtained with
scanning laser confocal microscopy through 100-mm thick myocardial
sections of infarct, border zone, and remote myocardial regions.
Three-dimensional reconstructions of the Z-stacks were created with Vo-
locity Software version 3.61 (Improvision Inc, Waltham, Mass).rdiovascular Surgery c Volume 140, Number 3 669
FIGURE 2. A, In vitro VEGF-A concentration steadily increased over 24
hours of 3DFC culture. B, In vitro HGF concentration followed a similar
pattern. VEGF, Vascular endothelial growth factor; HGF, hepatocyte
growth factor.




SFluorescein-labeled voxels were quantified as a percentage of total tissue
section voxels, creating a quantifiable measurement of perfusion per unit
of myocardial tissue volume.
Infarct Size and Ventricular Geometry Analysis
After myocardial functional analysis described below, hearts were ex-
planted (control, n ¼ 10; experimental, n ¼ 9). The left ventricle was filled
with OCT through the aorta at a pressure of 80 mm Hg, and the heart was
submerged in OCT, frozen, and stored at80C. Sections (10 mm) from
midway between the apex and point of ligation were prepared and stained
with hematoxylin and eosin. Measurements were performed on digitized
photomicrographs of the sections using Adobe Photoshop CS3 Extended
version 10.0 image processing software (Adobe Systems Inc, San Jose, Ca-
lif) with a standard of known length and were obtained on two sections for
each animal. Left ventricular internal diameter (LVID), border-zone wall
thickness, infarct area, and cross-sectional area of the entire heart were re-
corded for each of the sections.
Echocardiographic Assessment of Left Ventricular
(LV) Geometry and Function
Left ventricular (LV) geometry and function were evaluated by transtho-
racic echocardiography using a Phillips Sonos 5500 revD system (Phillips
Medical Systems NA, Bothwell, Wash) with a 12-MHz transducer at an im-
age depth of 2 cm. Rats (control, n ¼ 20; experimental, n ¼ 17) were anes-
thetized and placed in the dorsal recumbency position. Left parasternal LV
short axis 2-D and M-mode images were used to define LV free wall thick-
ness and LVID during systole and diastole. LV end-systolic diameter
(LVIDs) and end-diastolic diameter (LVIDd) were used to derive end-dia-
stolic volume (EDV, 1.047 3 LVIDd3), end-systolic volume (ESV,
1.047 3 LVIDs3), fractional shortening ([(LVIDd  LVIDs)/
LVIDd]3 100), stroke volume (EDVESV), and ejection fraction (stroke
volume/EDV 3 100).31
Invasive Hemodynamic Assessment
Eleven control and 8 experimental animals underwent invasive hemody-
namic measurements with a pressure–volume conductance catheter (SPR-
869; Millar Instruments, Inc, Houston, Tex). The catheter was calibrated
via 5-point cuvette linear interpolation with parallel conductance subtrac-
tion by the hypertonic saline method.26 Rats were anesthetized and the cath-
eter was introduced into the left ventricle with a closed-chest approach via
the right carotid artery. Measurements were obtained before and during in-
ferior vena cava occlusion to produce static and dynamic pressure–volume
loops under varying load conditions. Data were recorded and analyzed with
LabChart version 6 software (AD Instruments, Colorado Springs, Colo) and
ARIA Pressure Volume Analysis software (Millar Instruments).
Statistical Analysis
Analyses were performed in a blinded fashion. The unpaired Student
t test was used to compare groups. Values are expressed as mean standard
error of the mean.RESULTS
In Vitro Growth Factor Expression
VEGF-A concentrations in the growth medium at 0.5, 1,
1.5, 2, 3, 4, 10, and 24 hours were 18.8, 19.5, 21.0, 21.1,
23.4, 25.6, 29.9, and 54.3 pg/mL, respectively. HGF (un-
detectable, 57, 73, 113, 301, 325, 693, and 3533 pg/mL)
expression followed a similar pattern (Figure 2). Media-
only control samples demonstrated undetectable levels of
VEGF-A and HGF at all time points. This validated670 The Journal of Thoracic and Cardiovascular Surgthe expression of the angiogenic growth factors by the
3DFC.
Determination of Human Fibroblast Cell Fate
HFSP is present on the surface of human fibroblasts, and
antibodies directed againstHFSP showminimal cross-reactiv-
ity in rats. Therefore, immunoblotting for HFSP allowed us to
qualitatively assess presence of transplanted human fibroblast
components in the 3DFC group. Figure 3, A, shows expres-
sion of HFSP in control and 3DFC animals. Quantitative
analysis demonstrated a twofold increase in HFSP staining
among 3DFC animals (57.8  7.4 intensity units [IU]) com-
pared with controls (28.1  9.0 IU; P ¼ .022). These data
suggest that fractions of the transplanted fibroblasts survived.
In Vivo Growth Factor Expression/Mechanism of
Action
Immunoblotting revealed a statistically significant in-
crease in VEGF-A and HGF expression in 3DFC animals
(VEGF-A, 30.1  1.4 IU; HGF, 42.7  6.0 IU) versus con-
trols (VEGF-A, 18.2  1.5 IU; P< .001; HGF, 28.2  4.0
IU; P ¼ .049). Immunoblots are shown in Figure 3, B
(VEGF-A) and 3, C (HGF). These experiments suggest
that the 3DFC may continue to elute angiogenic growth
factors after implantation.ery c September 2010
FIGURE 3. A, Immunoblotting directed against human fibroblast surface protein 4 weeks after 3DFC scaffold implantation provides evidence of human
fibroblast survival in experimental animals. B, Experimental animals exhibited statistically significant upregulation in vascular endothelial growth factor
A expression 4 weeks after 3DFC implantation. C, 3DFC-treated animals also exhibited increase hepatocyte growth factor expression at 4 weeks. 3DFC,
3-dimensional human dermal fibroblast culture.
Fitzpatrick III et al Evolving Technology/Basic ScienceMicrovascular Angiogenesis Is Increased After 3DFC
Treatment
Analysis of immunofluorescent co-expression of PECAM
anda-SMA (Figure 4) revealed a significant increase in blood
vessel density in the infarct and border-zone regions of 3DFC
animals (infarct, 8.8  0.6 vessels/high-power field [hpf];
border zone, 8.4  0.4 vessels/hpf) compared with controls
(infarct, 1.8  0.3 vessels/hpf; P < .001; border zone,
1.8  0.1 vessels/hpf; P< .001). Vessel density in remote
myocardium was equivalent between 3DFC (8.4  0.3 ves-
sels/hpf) and control animals (9.3 0.7 vessels/hpf; P>.2).E
T
/B
SAugmentation of Microvascular Perfusion After
3DFC Treatment
Remote myocardial perfusion was equivalent between
3DFC and control groups (1.9% 0.3% vessel volume/tis-
sue volume versus 2.7% 0.4%; P>.2). This served as an
internal control, validating the assay and demonstrating sim-
ilar baseline perfusion in the two groups. Qualitative analysis
revealed increased perfusion among 3DFC animals in infarct
and border-zone regions (Figure 5). Quantitative analysis
demonstrated significantly enhanced perfusion in the ische-
mic areas in 3DFC (infarct, 1.6%  0.2%; border zone,
2.3%  0.4%) compared with control animals (infarct,
0.4%  0.1%; P ¼ .005; border zone, 0.7%  0.2%;
P¼ .041). In addition to demonstrating improved microvas-
cular perfusion of the ischemic zones after 3DFC treatment,
these data confirm the increase in vasculature that was noted
with PECAM/a-SMA vascular labeling.FIGURE 4. Representative images of myocardial sections depicting plate-
let endothelial cell adhesion molecule (PECAM, orange) and alpha smooth
muscle actin (a-SMA, green) in control (A) and 3DFC-treated hearts (B).Adverse Ventricular Remodeling Is Diminished After
3DFC Treatment
Infarct area and infarct fraction were significantly smaller
in 3DFC animals (area, 4.38  0.55 mm2; fraction,
8.07%  1.34%) versus controls (area, 8.64  0.87 mm2;The Journal of Thoracic and Cardiovascular Surgery c Volume 140, Number 3 671
FIGURE 5. After perfusion with lectin, 3-dimensional image stacks were obtained with confocal microscopy of control, remote myocardium (A), control,
peri-infarct border-zone myocardium (B), control, infarct myocardium (C), 3DFC-treated, remote myocardium (D), 3DFC-treated, peri-infarct border-zone
myocardium (E), and 3DFC-treated, infarct myocardium (F).




SP ¼ .001; fraction, 15.76%  1.09%; P<.001). A marked
increase in border-zone wall thickness was also observed in
the 3DFC group (3DFC, 1.53  0.11 mm; control,
1.07  0.08 mm; P ¼ .004). A trend toward smaller LVID
among the 3DFC group was also noted (3DFC,
8.49  1.34 mm; control, 9.74  0.29 mm; P ¼ .103).672 The Journal of Thoracic and Cardiovascular SurgEchocardiographic Assessment of LV Function and
Geometry
Echocardiographic assessment of cardiac structure and
function demonstrated significant benefits in the 3DFC
group versus the control group (Table 1, part A). Among
3DFC animals, LVID was smaller in both systole andery c September 2010
TABLE 1. Hemodynamic parameters of LV function and geometry 4
weeks after left anterior descending coronary artery ligation among
control and 3DFC-treated animals
Control 3DFC P value
A. Echocardiography (control, n ¼ 20; 3DFC, n ¼ 17)
LV internal diameter
diastole (cm)
0.770  0.026 0.689  0.025 .030
LV free wall thickness
diastole (cm)
0.107  0.006 0.160  0.013 .001
LV internal diameter
systole (cm)
0.638  0.030 0.497  0.024 .001
LV free wall thickness
systole (cm)
0.107  0.007 0.181  0.017 .001
Fractional shortening (%) 18  2 28  1 <.001
Ejection fraction (%) 44  3 63  2 <.001
B. Pressure–volume conductance catheter (control, n ¼ 11; 3DFC, n ¼ 8)
Heart rate (beats/min) 210  5 222  15 >.2
End-diastolic volume (mL) 160.50  11.01 130.99  11.85 .010
End-systolic volume (mL) 119.39  9.95 82.47  11.32 .002
End-diastolic pressure
(mm Hg)
13.55  1.02 16.66  2.34 .053
End-systolic pressure (mm Hg) 91.26  2.33 106.30  5.01 .001
dP/dt max (mmHg/s) 4238  234 5726  249 <.001
Pressure @ dP/dt max
(mm Hg)
63.87  1.81 75.31  4.77 .003
Volume @ dP/dt max (mL) 164.33  11.67 125.81  13.28 .004
Preload-adjusted maximal
power (mW/mL2)
13.78  1.56 17.48  4.27 .052
Slope of end-systolic pressure–
volume relationship
0.749  0.137 2.250  0.561 .005
Values were obtained using echocardiography and an intraventricular pressure–
volume conductance catheter, as indicated. Values are expressed as mean  standard
error of the mean. LV, Left ventricular; 3DFC, 3-dimensional human dermal fibroblast
culture; dP/dt max, maximum rate of pressure rise.




Sdiastole, whereas LV free wall thickness was greater. This
provides clear evidence that adverse ventricular remodeling
is diminished after treatment with the 3DFC. Additionally,
fractional shortening and LV ejection fraction were signifi-
cantly improved in 3DFC animals.
Invasive Hemodynamic Assessment
The3DFCanimals had statistically significant preservation
of cardiac function compared with controls (Table 1, part B).
The 3DFC group had improved EDV, ESV, end-diastolic and
end-systolic pressures, maximum rate of pressure rise (dP/dt
max), and preload adjusted maximal power. 3DFC animals
also had improved contractility, indicated by an increased
slope of the end-systolic pressure–volume relationship.
Representative pressure–volume loops are shown in Figure 6.
DISCUSSION
The prevalence and severity of ischemic cardiomyopathy,
combined with the moderate success of conventional revas-
cularization therapies, have prompted the development of
novel techniques specifically targeting the microvasculatureThe Journal of Thoracic and Cain ischemic myocardium. This study demonstrates the abil-
ity of a scaffold-based 3DFC to stimulate angiogenesis
within an area of myocardial ischemic injury. The angio-
genic response induced by the 3DFC resulted in improved
microvascular perfusion, which diminished adverse ventric-
ular remodeling and preserved myocardial function.
Preclinical studies of angiogenic growth factor therapy
have given significant insight into the biology of these
agents and have shown success in treating both peripheral
and cardiac ischemia.27,32-34 Although the results of ran-
domized controlled clinical trials are mixed, the potential
for clinical success remains.32-34 The current study and pre-
vious studies with the 3DFC are unique compared with other
angiogenic growth factor studies in that they use multiple
factors simultaneously expressed by a cellular source.23,24
Previous myocardial angiogenesis studies with the 3DFC
have used an SCID mouse model of ischemic cardiomyop-
athy to avoid immunologic tissue rejection by the host to-
ward the human cells.23,24 By contrast, our study uses
a model of ischemic cardiomyopathy in immunocompetent
rats. Our successful use of the 3DFC in immunocompetent
hosts establishes the 3DFC as a potentially translatable ther-
apy in recipients with normal immune function. Addition-
ally, the success of the 3DFC in healing chronic diabetic
foot wounds in patients with normal immune function fur-
ther supports the claim that this therapy will be clinically
translatable.
A related study has recently been published by Thai and
associates,35 which concluded that the 3DFC improved
LV function and blood flow after myocardial infarction in
immunocompetent rats. Although this work is promising,
our study builds on these findings. First, because both arti-
cles represent the first reports of this 3DFC in the treatment
of myocardial ischemia in immune-competent hosts, we be-
lieve it is important to prove that the 3DFC fibroblasts show
evidence of survival and function after xenotransplantation.
Additionally, invasive hemodynamic measurements in our
study showed improvements in EDV, ESV, EDP, ESP,
dP/dt max, pressure at dP/dt max, volume at dP/dt max, pre-
load-adjusted maximal power, and the slope of the end-
systolic pressure–volume relationship.
In our study, the 3DFC was proven to elute VEGF-A and
HGF in vitro. After application of the 3DFC to a region of
myocardial ischemia, fibroblasts showed evidence of sur-
vival up to 4 weeks, and the cells expressed these factors
at a higher level than control animals during this time period.
Sustained local delivery of VEGF-A and HGF led to signif-
icant upregulation of microvascular angiogenesis in the is-
chemic zones of the myocardium, evidenced by increased
density of vessels co-staining for PECAM and a-SMA.
The presence of a-SMA, a marker of pericyte presence in
the vessel wall, establishes that the new microvasculature
has achieved maturity. Additionally, lectin microvascular
angiograms demonstrated that the newly formedrdiovascular Surgery c Volume 140, Number 3 673
FIGURE 6. Representative pressure–volume loops obtained during steady state measurements from control (A) and 3DFC-treated animals (B). Represen-
tative pressure–volume loops obtained during inferior vena caval occlusion from control (C) and 3DFC-treated animals (D).




Smicrovascular networks are functionally perfused. Improved
microvascular perfusion was demonstrated in both infarct
and border-zone regions.
Because adverse ventricular remodeling and LV func-
tional loss are due to malperfusion that accompanies signif-
icant ischemic injury, it is expected that activation of
angiogenesis and improved microvascular perfusion will
limit adverse ventricular remodeling and preserve LV func-
tion. This study confirmed that expectation when LV geom-
etry and function were analyzed via multiple modalities,
including digital planimetric analysis of myocardial sec-
tions, echocardiography, and invasive pressure–volume
measurements. It is notable that the two previous SCID
mouse studies found no improvement in ventricular geome-
try or function among animals treated with an acellular
scaffold, suggesting that these benefits result from angiogen-674 The Journal of Thoracic and Cardiovascular Surgesis and enhanced perfusion, rather than the scaffold
itself.23,24
In addition to sustained delivery of angiogenic cyto-
kines, multiple other factors may be responsible for the
success of the 3DFC in inducing angiogenesis. For exam-
ple, most experimental angiogenic therapies are focused
on modulating the ischemic border zone. However, in
this study the therapeutic 3DFC is applied to the entire is-
chemic zone, which may prompt a more robust angiogenic
response. Additionally, as one of the key cellular compo-
nents in wound healing, fibroblasts may be ideally suited
to adapt to the ischemic milieu of the infarct, secreting
known and unknown angiogenic stimulants in physiologic
concentrations to optimize angiogenesis. It will be impor-
tant to address these questions in subsequent studies as An-
ginera transitions into the clinical domain. Futureery c September 2010
Fitzpatrick III et al Evolving Technology/Basic Scienceinvestigations should also elucidate the specific angiogenic
and anti-apoptotic pathways stimulated by the 3DFC and
determine whether a higher dose of fibroblasts, and there-
fore a higher dose of angiogenic cytokines, results in im-
proved angiogenesis.Limitations
There are multiple potential limitations to this study. First,
the study was not designed to evaluate whether the polygly-
colic acid mesh contributed to the survival and function of
the transplanted fibroblasts. Therefore, it is not possible to
assess whether the 3DFC represents an improvement over
direct cell transplantation with other cell types that have
been previously studied by other investigators. Further,
this study did not evaluate the use of a polyglycolic acid
mesh without cells as an additional control group. Finally,
the lectin studies evaluated microvascular perfusion. They
did not specifically evaluate perfusion of the individual car-
diomyocytes.CONCLUSIONS
This study demonstrates the ability of a tissue-engineered
3-dimensional fibroblast scaffold to stimulate angiogenesis,
improve microvascular perfusion, limit adverse ventricular
remodeling, and preserve ventricular function in ischemic
myocardium through sustained local delivery of angiogenic
growth factors. Therefore, it may, in the future, play a role in
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